ID   SGK1_HUMAN              Reviewed;         431 AA.
AC   O00141; B7UUP7; B7UUP8; B7UUP9; B7Z5B2; E1P583; Q5TCN2; Q5TCN3;
AC   Q5TCN4; Q5VY65; Q9UN56;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   07-MAR-2006, sequence version 2.
DT   15-MAR-2017, entry version 176.
DE   RecName: Full=Serine/threonine-protein kinase Sgk1;
DE            EC=2.7.11.1;
DE   AltName: Full=Serum/glucocorticoid-regulated kinase 1;
GN   Name=SGK1; Synonyms=SGK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9114008; DOI=10.1073/pnas.94.9.4440;
RA   Waldegger S., Barth P., Raber G., Lang F.;
RT   "Cloning and characterization of a putative human serine/threonine
RT   protein kinase transcriptionally modified during anisotonic and
RT   isotonic alterations of cell volume.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:4440-4445(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORM
RP   1).
RX   PubMed=9722955; DOI=10.1006/geno.1998.5258;
RA   Waldegger S., Erdel M., Nagl U.O., Barth P., Raber G., Steuer S.,
RA   Utermann G., Paulmichl M., Lang F.;
RT   "Genomic organization and chromosomal localization of the human SGK
RT   protein kinase gene.";
RL   Genomics 51:299-302(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, ALTERNATIVE PROMOTER
RP   USAGE, INDUCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=18753299; DOI=10.1152/ajprenal.90239.2008;
RA   Raikwar N.S., Snyder P.M., Thomas C.P.;
RT   "An evolutionarily conserved N-terminal Sgk1 variant with enhanced
RT   stability and improved function.";
RL   Am. J. Physiol. 295:F1440-F1448(2008).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3; 4 AND 5), AND ALTERNATIVE
RP   PROMOTER USAGE.
RC   TISSUE=Glioblastoma, Hippocampus, and Skin;
RA   Hall B.A., Blakeley S., Daniels N.A., Jamieson D., Brickley D.,
RA   Reynolds N.J., Conzen S.D., Jackson T.R.;
RT   "Transcriptional variants of serum/glucocorticoid regulated kinase 1
RT   show differential localisation and regulation.";
RL   Submitted (AUG-2008) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Hair follicle dermal papilla;
RA   Kim M.K., Kim Y.H., Seo J.M., Lee H.M., Chung H.J., Sohn M.Y.,
RA   Hwang S.Y., Im S.U., Jung E.J., Lee J.H., Kim J.C.;
RT   "A catalogue of genes in the human dermal papilla cells as identified
RT   by expressed sequence tags.";
RL   Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Cervix;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   TISSUE SPECIFICITY.
RX   PubMed=10548550; DOI=10.1042/bj3440189;
RA   Kobayashi T., Deak M., Morrice N., Cohen P.;
RT   "Characterization of the structure and regulation of two novel
RT   isoforms of serum- and glucocorticoid-induced protein kinase.";
RL   Biochem. J. 344:189-197(1999).
RN   [11]
RP   PHOSPHORYLATION AT THR-256 AND SER-422, AND MUTAGENESIS OF THR-256 AND
RP   SER-422.
RC   TISSUE=Brain;
RX   PubMed=10191262; DOI=10.1042/bj3390319;
RA   Kobayashi T., Cohen P.;
RT   "Activation of serum- and glucocorticoid-regulated protein kinase by
RT   agonists that activate phosphatidylinositide 3-kinase is mediated by
RT   3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2.";
RL   Biochem. J. 339:319-328(1999).
RN   [12]
RP   CHARACTERIZATION.
RX   PubMed=10884438; DOI=10.1073/pnas.97.14.8157;
RA   Lang F., Klingel K., Wagner C.A., Stegen C., Waerntges S.,
RA   Friedrich B., Lanzendoerfer M., Melzig J., Moschen I., Steuer S.,
RA   Waldegger S., Sauter M., Paulmichl M., Gerke V., Risler T., Gamba G.,
RA   Capasso G., Kandolf R., Hebert S.C., Massry S.G., Broer S.;
RT   "Deranged transcriptional regulation of cell-volume-sensitive kinase
RT   hSGK in diabetic nephropathy.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:8157-8162(2000).
RN   [13]
RP   PHOSPHORYLATION AT SER-78 BY MAPK7, AND INTERACTION WITH MAPK7.
RX   PubMed=11254654; DOI=10.1074/jbc.C000838200;
RA   Hayashi M., Tapping R.I., Chao T.H., Lo J.F., King C.C., Yang Y.,
RA   Lee J.D.;
RT   "BMK1 mediates growth factor-induced cell proliferation through direct
RT   cellular activation of serum and glucocorticoid-inducible kinase.";
RL   J. Biol. Chem. 276:8631-8634(2001).
RN   [14]
RP   PHOSPHORYLATION AT THR-369 BY PKA.
RX   PubMed=11096081; DOI=10.1074/jbc.M007052200;
RA   Perrotti N., He R.A., Phillips S.A., Haft C.R., Taylor S.I.;
RT   "Activation of serum- and glucocorticoid-induced protein kinase (Sgk)
RT   by cyclic AMP and insulin.";
RL   J. Biol. Chem. 276:9406-9412(2001).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF BRAF.
RX   PubMed=11410590; DOI=10.1074/jbc.M102808200;
RA   Zhang B.H., Tang E.D., Zhu T., Greenberg M.E., Vojtek A.B., Guan K.L.;
RT   "Serum- and glucocorticoid-inducible kinase SGK phosphorylates and
RT   negatively regulates B-Raf.";
RL   J. Biol. Chem. 276:31620-31626(2001).
RN   [16]
RP   FUNCTION.
RX   PubMed=11154281; DOI=10.1128/MCB.21.3.952-965.2001;
RA   Brunet A., Park J., Tran H., Hu L.S., Hemmings B.A., Greenberg M.E.;
RT   "Protein kinase SGK mediates survival signals by phosphorylating the
RT   forkhead transcription factor FKHRL1 (FOXO3a).";
RL   Mol. Cell. Biol. 21:952-965(2001).
RN   [17]
RP   INTERACTION WITH NEDD4 AND NEDD4L, MUTAGENESIS OF LYS-127; TYR-298 AND
RP   SER-422, AND FUNCTION.
RX   PubMed=11696533; DOI=10.1074/jbc.C100623200;
RA   Snyder P.M., Olson D.R., Thomas B.C.;
RT   "Serum and glucocorticoid-regulated kinase modulates Nedd4-2-mediated
RT   inhibition of the epithelial Na+ channel.";
RL   J. Biol. Chem. 277:5-8(2002).
RN   [18]
RP   FUNCTION IN REGULATION OF NA(+)/K(+) ATPASE.
RX   PubMed=12590200; DOI=10.1159/000068699;
RA   Henke G., Setiawan I., Boehmer C., Lang F.;
RT   "Activation of Na+/K+-ATPase by the serum and glucocorticoid-dependent
RT   kinase isoforms.";
RL   Kidney Blood Press. Res. 25:370-374(2002).
RN   [19]
RP   FUNCTION.
RX   PubMed=12397388; DOI=10.1007/s00424-002-0873-2;
RA   Gamper N., Fillon S., Feng Y., Friedrich B., Lang P.A., Henke G.,
RA   Huber S.M., Kobayashi T., Cohen P., Lang F.;
RT   "K(+) channel activation by all three isoforms of serum- and
RT   glucocorticoid-dependent protein kinase SGK.";
RL   Pflugers Arch. 445:60-66(2002).
RN   [20]
RP   FUNCTION, AND INTERACTION WITH SLC9A3R2/NHERF2 AND KCNJ1/ROMK1.
RX   PubMed=14623317; DOI=10.1016/j.bbrc.2003.10.037;
RA   Palmada M., Embark H.M., Yun C., Bohmer C., Lang F.;
RT   "Molecular requirements for the regulation of the renal outer
RT   medullary K(+) channel ROMK1 by the serum- and glucocorticoid-
RT   inducible kinase SGK1.";
RL   Biochem. Biophys. Res. Commun. 311:629-634(2003).
RN   [21]
RP   FUNCTION IN REGULATION OF SCN5A.
RX   PubMed=12650886; DOI=10.1016/S0008-6363(02)00837-4;
RA   Boehmer C., Wilhelm V., Palmada M., Wallisch S., Henke G.,
RA   Brinkmeier H., Cohen P., Pieske B., Lang F.;
RT   "Serum and glucocorticoid inducible kinases in the regulation of the
RT   cardiac sodium channel SCN5A.";
RL   Cardiovasc. Res. 57:1079-1084(2003).
RN   [22]
RP   FUNCTION IN PHOSPHORYLATION OF MAP3K3/MEKK3.
RX   PubMed=12761204; DOI=10.1093/jb/mvg010;
RA   Chun J., Kwon T., Kim D.J., Park I., Chung G., Lee E.J., Hong S.K.,
RA   Chang S.I., Kim H.Y., Kang S.S.;
RT   "Inhibition of mitogen-activated kinase kinase kinase 3 activity
RT   through phosphorylation by the serum- and glucocorticoid-induced
RT   kinase 1.";
RL   J. Biochem. 133:103-108(2003).
RN   [23]
RP   FUNCTION IN REGULATION OF KCNA3/KV1.3, AND MUTAGENESIS OF LYS-127 AND
RP   SER-422.
RX   PubMed=12911626;
RA   Boehmer C., Henke G., Schniepp R., Palmada M., Rothstein J.D.,
RA   Broeer S., Lang F.;
RT   "Regulation of the glutamate transporter EAAT1 by the ubiquitin ligase
RT   Nedd4-2 and the serum and glucocorticoid-inducible kinase isoforms
RT   SGK1/3 and protein kinase B.";
RL   J. Neurochem. 86:1181-1188(2003).
RN   [24]
RP   NUCLEAR LOCALIZATION SIGNAL.
RX   PubMed=12631736; DOI=10.1091/mbc.E02-03-0170;
RA   Maiyar A.C., Leong M.L., Firestone G.L.;
RT   "Importin-alpha mediates the regulated nuclear targeting of serum- and
RT   glucocorticoid-inducible protein kinase (Sgk) by recognition of a
RT   nuclear localization signal in the kinase central domain.";
RL   Mol. Biol. Cell 14:1221-1239(2003).
RN   [25]
RP   FUNCTION IN REGULATION OF KCNE1 AND KCNQ1.
RX   PubMed=12634932; DOI=10.1007/s00424-002-0982-y;
RA   Embark H.M., Boehmer C., Vallon V., Luft F., Lang F.;
RT   "Regulation of KCNE1-dependent K(+) current by the serum and
RT   glucocorticoid-inducible kinase (SGK) isoforms.";
RL   Pflugers Arch. 445:601-606(2003).
RN   [26]
RP   FUNCTION IN REGULATION OF SLC34A2/NAPI-2B, AND FUNCTION IN
RP   PHOSPHORYLATION OF NEDD4L.
RX   PubMed=15044175; DOI=10.1152/ajpgi.00121.2003;
RA   Palmada M., Dieter M., Speil A., Boehmer C., Mack A.F., Wagner H.J.,
RA   Klingel K., Kandolf R., Murer H., Biber J., Closs E.I., Lang F.;
RT   "Regulation of intestinal phosphate cotransporter NaPi IIb by
RT   ubiquitin ligase Nedd4-2 and by serum- and glucocorticoid-dependent
RT   kinase 1.";
RL   Am. J. Physiol. 287:G143-G150(2004).
RN   [27]
RP   FUNCTION IN REGULATION OF SLC13A2/NADC1.
RX   PubMed=14706641; DOI=10.1016/j.bbrc.2003.12.011;
RA   Boehmer C., Embark H.M., Bauer A., Palmada M., Yun C.H., Weinman E.J.,
RA   Endou H., Cohen P., Lahme S., Bichler K.H., Lang F.;
RT   "Stimulation of renal Na+ dicarboxylate cotransporter 1 by Na+/H+
RT   exchanger regulating factor 2, serum and glucocorticoid inducible
RT   kinase isoforms, and protein kinase B.";
RL   Biochem. Biophys. Res. Commun. 313:998-1003(2004).
RN   [28]
RP   FUNCTION IN REGULATION OF TRPV5.
RX   PubMed=15319523; DOI=10.1159/000080329;
RA   Embark H.M., Setiawan I., Poppendieck S., van de Graaf S.F.,
RA   Boehmer C., Palmada M., Wieder T., Gerstberger R., Cohen P., Yun C.C.,
RA   Bindels R.J., Lang F.;
RT   "Regulation of the epithelial Ca2+ channel TRPV5 by the NHE regulating
RT   factor NHERF2 and the serum and glucocorticoid inducible kinase
RT   isoforms SGK1 and SGK3 expressed in Xenopus oocytes.";
RL   Cell. Physiol. Biochem. 14:203-212(2004).
RN   [29]
RP   FUNCTION.
RX   PubMed=15234985; DOI=10.1074/jbc.M403260200;
RA   Diakov A., Korbmacher C.;
RT   "A novel pathway of epithelial sodium channel activation involves a
RT   serum- and glucocorticoid-inducible kinase consensus motif in the C
RT   terminus of the channel's alpha-subunit.";
RL   J. Biol. Chem. 279:38134-38142(2004).
RN   [30]
RP   FUNCTION, AND MUTAGENESIS OF LYS-127 AND SER-422.
RX   PubMed=15040001; DOI=10.1002/jcp.10430;
RA   Henke G., Maier G., Wallisch S., Boehmer C., Lang F.;
RT   "Regulation of the voltage gated K+ channel Kv1.3 by the ubiquitin
RT   ligase Nedd4-2 and the serum and glucocorticoid inducible kinase
RT   SGK1.";
RL   J. Cell. Physiol. 199:194-199(2004).
RN   [31]
RP   FUNCTION IN REGULATION OF BSND.
RX   PubMed=15496163; DOI=10.1111/j.1523-1755.2004.00966.x;
RA   Embark H.M., Boehmer C., Palmada M., Rajamanickam J., Wyatt A.W.,
RA   Wallisch S., Capasso G., Waldegger P., Seyberth H.W., Waldegger S.,
RA   Lang F.;
RT   "Regulation of CLC-Ka/barttin by the ubiquitin ligase Nedd4-2 and the
RT   serum- and glucocorticoid-dependent kinases.";
RL   Kidney Int. 66:1918-1925(2004).
RN   [32]
RP   FUNCTION IN PHOSPHORYLATION OF SLC9A3/NHE3.
RX   PubMed=15888551; DOI=10.1152/ajpcell.00597.2004;
RA   Wang D., Sun H., Lang F., Yun C.C.;
RT   "Activation of NHE3 by dexamethasone requires phosphorylation of NHE3
RT   at Ser663 by SGK1.";
RL   Am. J. Physiol. 289:C802-C810(2005).
RN   [33]
RP   FUNCTION IN REGULATION OF SLC1A5/ASCT2.
RX   PubMed=15845389; DOI=10.1016/j.bbrc.2005.03.159;
RA   Palmada M., Speil A., Jeyaraj S., Boehmer C., Lang F.;
RT   "The serine/threonine kinases SGK1, 3 and PKB stimulate the amino acid
RT   transporter ASCT2.";
RL   Biochem. Biophys. Res. Commun. 331:272-277(2005).
RN   [34]
RP   FUNCTION IN REGULATION OF SLC1A7/EAAT5.
RX   PubMed=15737648; DOI=10.1016/j.bbrc.2005.02.035;
RA   Boehmer C., Rajamanickam J., Schniepp R., Kohler K., Wulff P.,
RA   Kuhl D., Palmada M., Lang F.;
RT   "Regulation of the excitatory amino acid transporter EAAT5 by the
RT   serum and glucocorticoid dependent kinases SGK1 and SGK3.";
RL   Biochem. Biophys. Res. Commun. 329:738-742(2005).
RN   [35]
RP   FUNCTION IN REGULATION OF SLC6A8.
RX   PubMed=16036218; DOI=10.1016/j.bbrc.2005.06.164;
RA   Shojaiefard M., Christie D.L., Lang F.;
RT   "Stimulation of the creatine transporter SLC6A8 by the protein kinases
RT   SGK1 and SGK3.";
RL   Biochem. Biophys. Res. Commun. 334:742-746(2005).
RN   [36]
RP   FUNCTION IN PHOSPHORYLATION OF CREB1, AND INTERACTION WITH CREB1.
RX   PubMed=15733869; DOI=10.1016/j.febslet.2005.01.040;
RA   David S., Kalb R.G.;
RT   "Serum/glucocorticoid-inducible kinase can phosphorylate the cyclic
RT   AMP response element binding protein, CREB.";
RL   FEBS Lett. 579:1534-1538(2005).
RN   [37]
RP   UBIQUITINATION.
RX   PubMed=15576372; DOI=10.1074/jbc.M411053200;
RA   Zhou R., Snyder P.M.;
RT   "Nedd4-2 phosphorylation induces serum and glucocorticoid-regulated
RT   kinase (SGK) ubiquitination and degradation.";
RL   J. Biol. Chem. 280:4518-4523(2005).
RN   [38]
RP   FUNCTION IN REGULATION OF SLC2A1/GLUT1.
RX   PubMed=16443776; DOI=10.2337/diabetes.55.02.06.db05-0720;
RA   Palmada M., Boehmer C., Akel A., Rajamanickam J., Jeyaraj S.,
RA   Keller K., Lang F.;
RT   "SGK1 kinase upregulates GLUT1 activity and plasma membrane
RT   expression.";
RL   Diabetes 55:421-427(2006).
RN   [39]
RP   FUNCTION IN PHOSPHORYLATION OF MAPT/TAU, AND INTERACTION WITH
RP   MAPT/TAU.
RX   PubMed=16982696; DOI=10.1128/MCB.01017-06;
RA   Yang Y.C., Lin C.H., Lee E.H.;
RT   "Serum- and glucocorticoid-inducible kinase 1 (SGK1) increases neurite
RT   formation through microtubule depolymerization by SGK1 and by SGK1
RT   phosphorylation of tau.";
RL   Mol. Cell. Biol. 26:8357-8370(2006).
RN   [40]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17202226; DOI=10.1152/ajpcell.00399.2006;
RA   Cordas E., Naray-Fejes-Toth A., Fejes-Toth G.;
RT   "Subcellular location of serum- and glucocorticoid-induced kinase-1 in
RT   renal and mammary epithelial cells.";
RL   Am. J. Physiol. 292:C1971-C1981(2007).
RN   [41]
RP   FUNCTION IN PHOSPHORYLATION OF SLC2A4/GLUT4.
RX   PubMed=17382906; DOI=10.1016/j.bbrc.2007.03.029;
RA   Jeyaraj S., Boehmer C., Lang F., Palmada M.;
RT   "Role of SGK1 kinase in regulating glucose transport via glucose
RT   transporter GLUT4.";
RL   Biochem. Biophys. Res. Commun. 356:629-635(2007).
RN   [42]
RP   FUNCTION IN REGULATION OF TRPV6.
RX   PubMed=18005662; DOI=10.1016/j.febslet.2007.11.006;
RA   Boehmer C., Palmada M., Kenngott C., Lindner R., Klaus F., Laufer J.,
RA   Lang F.;
RT   "Regulation of the epithelial calcium channel TRPV6 by the serum and
RT   glucocorticoid-inducible kinase isoforms SGK1 and SGK3.";
RL   FEBS Lett. 581:5586-5590(2007).
RN   [43]
RP   FUNCTION IN PHOSPHORYLATION OF APBB1/FE65.
RX   PubMed=18304449; DOI=10.5483/BMBRep.2008.41.1.041;
RA   Lee E.J., Chun J., Hyun S., Ahn H.R., Jeong J.M., Hong S.K.,
RA   Hong J.T., Chang I.K., Jeon H.Y., Han Y.S., Auh C.K., Park J.I.,
RA   Kang S.S.;
RT   "Regulation Fe65 localization to the nucleus by SGK1 phosphorylation
RT   of its Ser566 residue.";
RL   BMB Rep. 41:41-47(2008).
RN   [44]
RP   PHOSPHORYLATION AT SER-422 BY MTORC2.
RX   PubMed=18925875; DOI=10.1042/BJ20081668;
RA   Garcia-Martinez J.M., Alessi D.R.;
RT   "mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation
RT   and activation of serum- and glucocorticoid-induced protein kinase 1
RT   (SGK1).";
RL   Biochem. J. 416:375-385(2008).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-74; SER-397 AND SER-401,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [46]
RP   ALTERNATIVE PROMOTER USAGE (ISOFORMS 2 AND 3).
RX   PubMed=18334630; DOI=10.1073/pnas.0800958105;
RA   Arteaga M.F., Coric T., Straub C., Canessa C.M.;
RT   "A brain-specific SGK1 splice isoform regulates expression of ASIC1 in
RT   neurons.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:4459-4464(2008).
RN   [47]
RP   PHOSPHORYLATION AT SER-397 AND SER-401.
RX   PubMed=19068477; DOI=10.1074/jbc.M807502200;
RA   Chen W., Chen Y., Xu B.E., Juang Y.C., Stippec S., Zhao Y., Cobb M.H.;
RT   "Regulation of a third conserved phosphorylation site in SGK1.";
RL   J. Biol. Chem. 284:3453-3460(2009).
RN   [48]
RP   FUNCTION IN PHOSPHORYLATION OF MAPK1/ERK2, AND INTERACTION WITH
RP   MAPK3/ERK1; MAPK1/ERK2; MAP2K1/MEK1 AND MAP2K2/MEK2.
RX   PubMed=19447520; DOI=10.1016/j.jhep.2009.02.027;
RA   Won M., Park K.A., Byun H.S., Kim Y.R., Choi B.L., Hong J.H., Park J.,
RA   Seok J.H., Lee Y.H., Cho C.H., Song I.S., Kim Y.K., Shen H.M.,
RA   Hur G.M.;
RT   "Protein kinase SGK1 enhances MEK/ERK complex formation through the
RT   phosphorylation of ERK2: implication for the positive regulatory role
RT   of SGK1 on the ERK function during liver regeneration.";
RL   J. Hepatol. 51:67-76(2009).
RN   [49]
RP   FUNCTION IN PHOSPHORYLATION OF MDM2.
RX   PubMed=19756449; DOI=10.1007/s00109-009-0525-5;
RA   Amato R., D'Antona L., Porciatti G., Agosti V., Menniti M.,
RA   Rinaldo C., Costa N., Bellacchio E., Mattarocci S., Fuiano G.,
RA   Soddu S., Paggi M.G., Lang F., Perrotti N.;
RT   "Sgk1 activates MDM2-dependent p53 degradation and affects cell
RT   proliferation, survival, and differentiation.";
RL   J. Mol. Med. 87:1221-1239(2009).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-74; SER-397 AND SER-401,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [51]
RP   FUNCTION IN REGULATION OF SLC6A19.
RX   PubMed=20511718; DOI=10.1159/000315092;
RA   Boehmer C., Sopjani M., Klaus F., Lindner R., Laufer J., Jeyaraj S.,
RA   Lang F., Palmada M.;
RT   "The serum and glucocorticoid inducible kinases SGK1-3 stimulate the
RT   neutral amino acid transporter SLC6A19.";
RL   Cell. Physiol. Biochem. 25:723-732(2010).
RN   [52]
RP   PHOSPHORYLATION AT SER-422 BY MTORC2, AND INTERACTION WITH MTORC2.
RX   PubMed=20338997; DOI=10.1681/ASN.2009111168;
RA   Lu M., Wang J., Jones K.T., Ives H.E., Feldman M.E., Yao L.J.,
RA   Shokat K.M., Ashrafi K., Pearce D.;
RT   "mTOR complex-2 activates ENaC by phosphorylating SGK1.";
RL   J. Am. Soc. Nephrol. 21:811-818(2010).
RN   [53]
RP   FUNCTION.
RX   PubMed=20730100; DOI=10.1371/journal.pone.0012163;
RA   Wiemuth D., Lott J.S., Ly K., Ke Y., Teesdale-Spittle P., Snyder P.M.,
RA   McDonald F.J.;
RT   "Interaction of serum- and glucocorticoid regulated kinase 1 (SGK1)
RT   with the WW-domains of Nedd4-2 is required for epithelial sodium
RT   channel regulation.";
RL   PLoS ONE 5:E12163-E12163(2010).
RN   [54]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-397, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [55]
RP   FUNCTION IN REGULATION OF SLC9A3/NHE3, AND SUBCELLULAR LOCATION.
RX   PubMed=21865597; DOI=10.1091/mbc.E11-04-0328;
RA   He P., Lee S.J., Lin S., Seidler U., Lang F., Fejes-Toth G.,
RA   Naray-Fejes-Toth A., Yun C.C.;
RT   "Serum- and glucocorticoid-induced kinase 3 in recycling endosomes
RT   mediates acute activation of Na+/H+ exchanger NHE3 by
RT   glucocorticoids.";
RL   Mol. Biol. Cell 22:3812-3825(2011).
RN   [56]
RP   REVIEW.
RX   PubMed=12649597; DOI=10.1159/000070244;
RA   Firestone G.L., Giampaolo J.R., O'Keeffe B.A.;
RT   "Stimulus-dependent regulation of serum and glucocorticoid inducible
RT   protein kinase (SGK) transcription, subcellular localization and
RT   enzymatic activity.";
RL   Cell. Physiol. Biochem. 13:1-12(2003).
RN   [57]
RP   REVIEW.
RX   PubMed=16460280; DOI=10.1146/annurev.physiol.68.040104.131654;
RA   Loffing J., Flores S.Y., Staub O.;
RT   "Sgk kinases and their role in epithelial transport.";
RL   Annu. Rev. Physiol. 68:461-490(2006).
RN   [58]
RP   REVIEW ON FUNCTION.
RX   PubMed=20919962; DOI=10.3109/08977194.2010.518616;
RA   Bruhn M.A., Pearson R.B., Hannan R.D., Sheppard K.E.;
RT   "Second AKT: the rise of SGK in cancer signalling.";
RL   Growth Factors 28:394-408(2010).
RN   [59]
RP   REVIEW ON FUNCTION.
RX   PubMed=20530112; DOI=10.1113/jphysiol.2010.190926;
RA   Lang F., Strutz-Seebohm N., Seebohm G., Lang U.E.;
RT   "Significance of SGK1 in the regulation of neuronal function.";
RL   J. Physiol. (Lond.) 588:3349-3354(2010).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 60-431, SUBUNIT, AND
RP   DISULFIDE BOND.
RX   PubMed=17965184; DOI=10.1110/ps.073161707;
RA   Zhao B., Lehr R., Smallwood A.M., Ho T.F., Maley K., Randall T.,
RA   Head M.S., Koretke K.K., Schnackenberg C.G.;
RT   "Crystal structure of the kinase domain of serum and glucocorticoid-
RT   regulated kinase 1 in complex with AMP PNP.";
RL   Protein Sci. 16:2761-2769(2007).
RN   [61]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-219 AND VAL-342.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase which is involved in the
CC       regulation of a wide variety of ion channels, membrane
CC       transporters, cellular enzymes, transcription factors, neuronal
CC       excitability, cell growth, proliferation, survival, migration and
CC       apoptosis. Plays an important role in cellular stress response.
CC       Contributes to regulation of renal Na(+) retention, renal K(+)
CC       elimination, salt appetite, gastric acid secretion, intestinal
CC       Na(+)/H(+) exchange and nutrient transport, insulin-dependent salt
CC       sensitivity of blood pressure, salt sensitivity of peripheral
CC       glucose uptake, cardiac repolarization and memory consolidation.
CC       Up-regulates Na(+) channels: SCNN1A/ENAC, SCN5A and ASIC1/ACCN2,
CC       K(+) channels: KCNJ1/ROMK1, KCNA1-5, KCNQ1-5 and KCNE1, epithelial
CC       Ca(2+) channels: TRPV5 and TRPV6, chloride channels: BSND, CLCN2
CC       and CFTR, glutamate transporters: SLC1A3/EAAT1, SLC1A2 /EAAT2,
CC       SLC1A1/EAAT3, SLC1A6/EAAT4 and SLC1A7/EAAT5, amino acid
CC       transporters: SLC1A5/ASCT2, SLC38A1/SN1 and SLC6A19, creatine
CC       transporter: SLC6A8, Na(+)/dicarboxylate cotransporter:
CC       SLC13A2/NADC1, Na(+)-dependent phosphate cotransporter:
CC       SLC34A2/NAPI-2B, glutamate receptor: GRIK2/GLUR6. Up-regulates
CC       carriers: SLC9A3/NHE3, SLC12A1/NKCC2, SLC12A3/NCC, SLC5A3/SMIT,
CC       SLC2A1/GLUT1, SLC5A1/SGLT1 and SLC15A2/PEPT2. Regulates enzymes:
CC       GSK3A/B, PMM2 and Na(+)/K(+) ATPase, and transcription factors:
CC       CTNNB1 and nuclear factor NF-kappa-B. Stimulates sodium transport
CC       into epithelial cells by enhancing the stability and expression of
CC       SCNN1A/ENAC. This is achieved by phosphorylating the NEDD4L
CC       ubiquitin E3 ligase, promoting its interaction with 14-3-3
CC       proteins, thereby preventing it from binding to SCNN1A/ENAC and
CC       targeting it for degradation. Regulates store-operated Ca(+2)
CC       entry (SOCE) by stimulating ORAI1 and STIM1. Regulates KCNJ1/ROMK1
CC       directly via its phosphorylation or indirectly via increased
CC       interaction with SLC9A3R2/NHERF2. Phosphorylates MDM2 and
CC       activates MDM2-dependent ubiquitination of p53/TP53.
CC       Phosphorylates MAPT/TAU and mediates microtubule depolymerization
CC       and neurite formation in hippocampal neurons. Phosphorylates
CC       SLC2A4/GLUT4 and up-regulates its activity. Phosphorylates
CC       APBB1/FE65 and promotes its localization to the nucleus.
CC       Phosphorylates MAPK1/ERK2 and activates it by enhancing its
CC       interaction with MAP2K1/MEK1 and MAP2K2/MEK2. Phosphorylates FBXW7
CC       and plays an inhibitory role in the NOTCH1 signaling.
CC       Phosphorylates FOXO1 resulting in its relocalization from the
CC       nucleus to the cytoplasm. Phosphorylates FOXO3, promoting its exit
CC       from the nucleus and interference with FOXO3-dependent
CC       transcription. Phosphorylates BRAF and MAP3K3/MEKK3 and inhibits
CC       their activity. Phosphorylates SLC9A3/NHE3 in response to
CC       dexamethasone, resulting in its activation and increased
CC       localization at the cell membrane. Phosphorylates CREB1. Necessary
CC       for vascular remodeling during angiogenesis. Sustained high levels
CC       and activity may contribute to conditions such as hypertension and
CC       diabetic nephropathy. Isoform 2 exhibited a greater effect on cell
CC       plasma membrane expression of SCNN1A/ENAC and Na(+) transport than
CC       isoform 1. {ECO:0000269|PubMed:11154281,
CC       ECO:0000269|PubMed:11410590, ECO:0000269|PubMed:11696533,
CC       ECO:0000269|PubMed:12397388, ECO:0000269|PubMed:12590200,
CC       ECO:0000269|PubMed:12634932, ECO:0000269|PubMed:12650886,
CC       ECO:0000269|PubMed:12761204, ECO:0000269|PubMed:12911626,
CC       ECO:0000269|PubMed:14623317, ECO:0000269|PubMed:14706641,
CC       ECO:0000269|PubMed:15040001, ECO:0000269|PubMed:15044175,
CC       ECO:0000269|PubMed:15234985, ECO:0000269|PubMed:15319523,
CC       ECO:0000269|PubMed:15496163, ECO:0000269|PubMed:15733869,
CC       ECO:0000269|PubMed:15737648, ECO:0000269|PubMed:15845389,
CC       ECO:0000269|PubMed:15888551, ECO:0000269|PubMed:16036218,
CC       ECO:0000269|PubMed:16443776, ECO:0000269|PubMed:16982696,
CC       ECO:0000269|PubMed:17382906, ECO:0000269|PubMed:18005662,
CC       ECO:0000269|PubMed:18304449, ECO:0000269|PubMed:18753299,
CC       ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:19756449,
CC       ECO:0000269|PubMed:20511718, ECO:0000269|PubMed:20730100,
CC       ECO:0000269|PubMed:21865597}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Two specific sites, one in the kinase domain
CC       (Thr-256) and the other in the C-terminal regulatory region (Ser-
CC       422), need to be phosphorylated for its full activation.
CC       Phosphorylation at Ser-397 and Ser-401 are also essential for its
CC       activity. Activated by WNK1, WNK2, WNK3 and WNK4.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Forms a trimeric complex
CC       with FBXW7 and NOTCH1. Interacts with MAPK3/ERK1, MAPK1/ERK2,
CC       MAP2K1/MEK1, MAP2K2/MEK2, NEDD4, NEDD4L, MAPT/TAU, MAPK7, CREB1,
CC       SLC9A3R2/NHERF2 and KCNJ1/ROMK1. Associates with the mammalian
CC       target of rapamycin complex 2 (mTORC2) via an interaction with
CC       MAPKAP1/SIN1. {ECO:0000269|PubMed:11254654,
CC       ECO:0000269|PubMed:11696533, ECO:0000269|PubMed:14623317,
CC       ECO:0000269|PubMed:15733869, ECO:0000269|PubMed:16982696,
CC       ECO:0000269|PubMed:17965184, ECO:0000269|PubMed:19447520,
CC       ECO:0000269|PubMed:20338997}.
CC   -!- INTERACTION:
CC       P49815:TSC2; NbExp=4; IntAct=EBI-1042854, EBI-396587;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Endoplasmic reticulum
CC       membrane. Cell membrane. Mitochondrion. Note=The subcellular
CC       localization is controlled by the cell cycle, as well as by
CC       exposure to specific hormones and environmental stress stimuli. In
CC       proliferating cells, it shuttles between the nucleus and cytoplasm
CC       in synchrony with the cell cycle, and in serum/growth factor-
CC       stimulated cells it resides in the nucleus. In contrast, after
CC       exposure to environmental stress or treatment with
CC       glucocorticoids, it is detected in the cytoplasm and with certain
CC       stress conditions is associated with the mitochondria. In
CC       osmoregulation through the epithelial sodium channel, it can be
CC       localized to the cytoplasmic surface of the cell membrane.
CC       Nuclear, upon phosphorylation.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=O00141-1; Sequence=Displayed;
CC       Name=2; Synonyms=Sgk1.1, Sgk1_v2;
CC         IsoId=O00141-2; Sequence=VSP_037784;
CC         Note=Produced by alternative promoter usage.;
CC       Name=3; Synonyms=Sgk1.2;
CC         IsoId=O00141-3; Sequence=VSP_037785;
CC         Note=Produced by alternative promoter usage.;
CC       Name=4;
CC         IsoId=O00141-4; Sequence=VSP_037786;
CC         Note=Produced by alternative splicing of isoform 1.;
CC       Name=5;
CC         IsoId=O00141-5; Sequence=VSP_037787;
CC         Note=Produced by alternative promoter usage.;
CC   -!- TISSUE SPECIFICITY: Expressed in most tissues with highest levels
CC       in the pancreas, followed by placenta, kidney and lung. Isoform 2
CC       is strongly expressed in brain and pancreas, weaker in heart,
CC       placenta, lung, liver and skeletal muscle.
CC       {ECO:0000269|PubMed:10548550, ECO:0000269|PubMed:18753299}.
CC   -!- INDUCTION: Induced by a very large spectrum of stimuli distinct
CC       from glucocorticoids and serum. These include aldosterone, cell
CC       shrinkage, cell swelling, TGF-beta, ischemic injury of the brain,
CC       neuronal excitotoxicity memory consolidation, chronic viral
CC       hepatitis, DNA-damaging agents, vitamin D3 psychophysiological
CC       stress, iron, glucose, EDN1, CSF2, fibroblast growth factor,
CC       platelet-derived growth factor, phorbolesters, follicle-
CC       stimulating hormone, sorbitol, heat shock, oxidative stress, UV
CC       irradiation, and p53/TP53. Many of these stimuli are highly cell-
CC       specific, as is the case, for example for aldosterone, which has
CC       been found to stimulate its expression only in cells derived from
CC       aldosterone-responsive epithelia. Isoform 2 is not induced by
CC       glucocorticoids but by excessive extracellular glucose and by
CC       TGFB1, in cultured cells. {ECO:0000269|PubMed:18753299}.
CC   -!- DOMAIN: Isoform 2 subcellular localization at the cell membrane
CC       and resistance to proteasomal degradation is mediated by the
CC       sequences within the first 120 amino acids.
CC   -!- PTM: Regulated by phosphorylation. Activated by phosphorylation on
CC       Ser-422 by mTORC2, transforming it into a substrate for PDPK1
CC       which phosphorylates it on Thr-256. Phosphorylation on Ser-397 and
CC       Ser-401 are also essential for its activity. Phosphorylation on
CC       Ser-78 by MAPK7 is required for growth factor-induced cell cycle
CC       progression. {ECO:0000269|PubMed:10191262,
CC       ECO:0000269|PubMed:11096081, ECO:0000269|PubMed:11254654,
CC       ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:19068477,
CC       ECO:0000269|PubMed:20338997}.
CC   -!- PTM: Ubiquitinated by NEDD4L; which promotes proteasomal
CC       degradation. Ubiquitinated by SYVN1 at the endoplasmic reticulum;
CC       which promotes rapid proteasomal degradation and maintains a high
CC       turnover rate in resting cells. Isoform 2 shows enhanced
CC       stability. {ECO:0000269|PubMed:15576372}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y10032; CAA71138.1; -; mRNA.
DR   EMBL; AJ000512; CAA04146.1; -; Genomic_DNA.
DR   EMBL; EU518415; ACD35864.1; -; mRNA.
DR   EMBL; FM205707; CAR58095.1; -; mRNA.
DR   EMBL; FM205708; CAR58096.1; -; mRNA.
DR   EMBL; FM205709; CAR58097.1; -; mRNA.
DR   EMBL; FM205710; CAR58098.1; -; mRNA.
DR   EMBL; AF153609; AAD41091.1; -; mRNA.
DR   EMBL; AK055077; BAG51463.1; -; mRNA.
DR   EMBL; AK298688; BAH12848.1; -; mRNA.
DR   EMBL; AL355881; CAH72579.1; -; Genomic_DNA.
DR   EMBL; AL135839; CAH72579.1; JOINED; Genomic_DNA.
DR   EMBL; Z84486; CAH72579.1; JOINED; Genomic_DNA.
DR   EMBL; AL135839; CAI19718.1; -; Genomic_DNA.
DR   EMBL; AL135839; CAI19719.1; -; Genomic_DNA.
DR   EMBL; AL135839; CAI19720.1; -; Genomic_DNA.
DR   EMBL; AL135839; CAI19721.1; -; Genomic_DNA.
DR   EMBL; AL355881; CAI19721.1; JOINED; Genomic_DNA.
DR   EMBL; Z84486; CAI19721.1; JOINED; Genomic_DNA.
DR   EMBL; Z84486; CAI21678.1; -; Genomic_DNA.
DR   EMBL; AL135839; CAI21678.1; JOINED; Genomic_DNA.
DR   EMBL; AL355881; CAI21678.1; JOINED; Genomic_DNA.
DR   EMBL; CH471051; EAW47991.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW47992.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW47993.1; -; Genomic_DNA.
DR   EMBL; BC001263; AAH01263.1; -; mRNA.
DR   CCDS; CCDS47476.1; -. [O00141-2]
DR   CCDS; CCDS47477.1; -. [O00141-5]
DR   CCDS; CCDS47478.1; -. [O00141-3]
DR   CCDS; CCDS5170.1; -. [O00141-1]
DR   RefSeq; NP_001137148.1; NM_001143676.1. [O00141-2]
DR   RefSeq; NP_001137149.1; NM_001143677.1. [O00141-5]
DR   RefSeq; NP_001137150.1; NM_001143678.1. [O00141-3]
DR   RefSeq; NP_001278924.1; NM_001291995.1.
DR   RefSeq; NP_005618.2; NM_005627.3. [O00141-1]
DR   RefSeq; XP_011534373.1; XM_011536071.1. [O00141-2]
DR   UniGene; Hs.510078; -.
DR   PDB; 2R5T; X-ray; 1.90 A; A=60-431.
DR   PDB; 3HDM; X-ray; 2.60 A; A=60-431.
DR   PDB; 3HDN; X-ray; 3.10 A; A=60-431.
DR   PDBsum; 2R5T; -.
DR   PDBsum; 3HDM; -.
DR   PDBsum; 3HDN; -.
DR   ProteinModelPortal; O00141; -.
DR   SMR; O00141; -.
DR   BioGrid; 112344; 61.
DR   DIP; DIP-42464N; -.
DR   IntAct; O00141; 13.
DR   MINT; MINT-1338693; -.
DR   STRING; 9606.ENSP00000356832; -.
DR   BindingDB; O00141; -.
DR   ChEMBL; CHEMBL2343; -.
DR   DrugBank; DB03247; Riboflavin Monophosphate.
DR   GuidetoPHARMACOLOGY; 1534; -.
DR   iPTMnet; O00141; -.
DR   PhosphoSitePlus; O00141; -.
DR   BioMuta; SGK1; -.
DR   MaxQB; O00141; -.
DR   PaxDb; O00141; -.
DR   PeptideAtlas; O00141; -.
DR   PRIDE; O00141; -.
DR   DNASU; 6446; -.
DR   Ensembl; ENST00000237305; ENSP00000237305; ENSG00000118515. [O00141-1]
DR   Ensembl; ENST00000367857; ENSP00000356831; ENSG00000118515. [O00141-4]
DR   Ensembl; ENST00000367858; ENSP00000356832; ENSG00000118515. [O00141-2]
DR   Ensembl; ENST00000413996; ENSP00000396242; ENSG00000118515. [O00141-3]
DR   Ensembl; ENST00000528577; ENSP00000434450; ENSG00000118515. [O00141-5]
DR   GeneID; 6446; -.
DR   KEGG; hsa:6446; -.
DR   UCSC; uc003qen.5; human. [O00141-1]
DR   CTD; 6446; -.
DR   DisGeNET; 6446; -.
DR   GeneCards; SGK1; -.
DR   HGNC; HGNC:10810; SGK1.
DR   HPA; CAB022085; -.
DR   HPA; CAB025148; -.
DR   HPA; HPA051251; -.
DR   MIM; 602958; gene.
DR   neXtProt; NX_O00141; -.
DR   OpenTargets; ENSG00000118515; -.
DR   PharmGKB; PA162403013; -.
DR   eggNOG; KOG0598; Eukaryota.
DR   eggNOG; ENOG410XNPH; LUCA.
DR   GeneTree; ENSGT00860000133668; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; O00141; -.
DR   KO; K13302; -.
DR   OMA; EVKEPCN; -.
DR   OrthoDB; EOG091G06FF; -.
DR   PhylomeDB; O00141; -.
DR   TreeFam; TF320906; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-2672351; Stimuli-sensing channels.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   SignaLink; O00141; -.
DR   SIGNOR; O00141; -.
DR   ChiTaRS; SGK1; human.
DR   EvolutionaryTrace; O00141; -.
DR   GeneWiki; SGK; -.
DR   GenomeRNAi; 6446; -.
DR   PRO; PR:O00141; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000118515; -.
DR   CleanEx; HS_SGK1; -.
DR   ExpressionAtlas; O00141; baseline and differential.
DR   Genevisible; O00141; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005246; F:calcium channel regulator activity; TAS:UniProtKB.
DR   GO; GO:0017081; F:chloride channel regulator activity; TAS:UniProtKB.
DR   GO; GO:0015459; F:potassium channel regulator activity; TAS:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:MGI.
DR   GO; GO:0017080; F:sodium channel regulator activity; TAS:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0034220; P:ion transmembrane transport; TAS:Reactome.
DR   GO; GO:0007616; P:long-term memory; TAS:UniProtKB.
DR   GO; GO:0048812; P:neuron projection morphogenesis; IBA:GO_Central.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0032411; P:positive regulation of transporter activity; TAS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0008217; P:regulation of blood pressure; TAS:UniProtKB.
DR   GO; GO:0050790; P:regulation of catalytic activity; TAS:UniProtKB.
DR   GO; GO:0001558; P:regulation of cell growth; TAS:UniProtKB.
DR   GO; GO:0030334; P:regulation of cell migration; TAS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; TAS:UniProtKB.
DR   GO; GO:0060453; P:regulation of gastric acid secretion; TAS:UniProtKB.
DR   GO; GO:0051090; P:regulation of sequence-specific DNA binding transcription factor activity; TAS:UniProtKB.
DR   GO; GO:0070294; P:renal sodium ion absorption; TAS:UniProtKB.
DR   GO; GO:0006950; P:response to stress; TAS:ProtInc.
DR   GO; GO:0006814; P:sodium ion transport; TAS:ProtInc.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative promoter usage; Alternative splicing;
KW   Apoptosis; ATP-binding; Cell membrane; Complete proteome; Cytoplasm;
KW   Disulfide bond; Endoplasmic reticulum; Kinase; Membrane;
KW   Mitochondrion; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Stress response; Transferase; Ubl conjugation.
FT   CHAIN         1    431       Serine/threonine-protein kinase Sgk1.
FT                                /FTId=PRO_0000086642.
FT   DOMAIN       98    355       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      356    431       AGC-kinase C-terminal.
FT   NP_BIND     104    112       ATP.
FT   REGION        1     60       Necessary for localization to the
FT                                mitochondria.
FT   MOTIF       131    141       Nuclear localization signal.
FT                                {ECO:0000269|PubMed:12631736}.
FT   COMPBIAS    131    141       Glu/Lys-rich.
FT   ACT_SITE    222    222       Proton acceptor.
FT   BINDING     127    127       ATP.
FT   MOD_RES      74     74       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES      78     78       Phosphoserine; by MAPK7.
FT                                {ECO:0000269|PubMed:11254654}.
FT   MOD_RES     256    256       Phosphothreonine; by PDPK1.
FT                                {ECO:0000269|PubMed:10191262}.
FT   MOD_RES     369    369       Phosphothreonine; by PKA.
FT                                {ECO:0000269|PubMed:11096081}.
FT   MOD_RES     397    397       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000269|PubMed:19068477}.
FT   MOD_RES     401    401       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:19068477}.
FT   MOD_RES     422    422       Phosphoserine.
FT                                {ECO:0000269|PubMed:10191262,
FT                                ECO:0000269|PubMed:18925875,
FT                                ECO:0000269|PubMed:20338997}.
FT   DISULFID    193    193       Interchain (with C-258).
FT                                {ECO:0000269|PubMed:17965184}.
FT   DISULFID    258    258       Interchain (with C-193).
FT                                {ECO:0000269|PubMed:17965184}.
FT   VAR_SEQ       1     25       MTVKTEAAKGTLTYSRMRGMVAILI -> MVNKDMNGFPVK
FT                                KCSAFQFFKKRVRRWIKSPMVSVDKHQSPSLKYTGSSMVHI
FT                                PPGEPDFESSLCQTCLGEHAFQRGVLPQENESCSWETQSGC
FT                                EVREPCNHANILTKPDPRTFWTNDDP (in isoform
FT                                2). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:18753299,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_037784.
FT   VAR_SEQ       1     25       MTVKTEAAKGTLTYSRMRGMVAILI -> MGEMQGALARAR
FT                                LESLLRPRHKKRAEAQKRSESFLLSGL (in isoform
FT                                3). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_037785.
FT   VAR_SEQ       1     25       MTVKTEAAKGTLTYSRMRGMVAILI -> MKPSKRFFISPP
FT                                SST (in isoform 4). {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_037786.
FT   VAR_SEQ       1     25       MTVKTEAAKGTLTYSRMRGMVAILI -> MSSQSSSLSEAC
FT                                SREAYSSHNWALPPASRSNPQPAYPWATRRMKEEAIKPPLK
FT                                (in isoform 5). {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_037787.
FT   VARIANT     219    219       V -> I (in dbSNP:rs34133418).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041071.
FT   VARIANT     342    342       A -> V (in dbSNP:rs55932330).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041072.
FT   MUTAGEN     127    127       K->M: Abolishes enzymatic activity.
FT                                {ECO:0000269|PubMed:11696533,
FT                                ECO:0000269|PubMed:12911626,
FT                                ECO:0000269|PubMed:15040001}.
FT   MUTAGEN     256    256       T->A: Low activity.
FT                                {ECO:0000269|PubMed:10191262}.
FT   MUTAGEN     256    256       T->D: Low activity.
FT                                {ECO:0000269|PubMed:10191262}.
FT   MUTAGEN     256    256       T->E: Low activity.
FT                                {ECO:0000269|PubMed:10191262}.
FT   MUTAGEN     298    298       Y->A: Abolishes interaction with NEDD4
FT                                and NEDD4L.
FT                                {ECO:0000269|PubMed:11696533}.
FT   MUTAGEN     422    422       S->A: Low activity.
FT                                {ECO:0000269|PubMed:10191262,
FT                                ECO:0000269|PubMed:11696533,
FT                                ECO:0000269|PubMed:12911626,
FT                                ECO:0000269|PubMed:15040001}.
FT   MUTAGEN     422    422       S->D: 10-fold activation.
FT                                {ECO:0000269|PubMed:10191262,
FT                                ECO:0000269|PubMed:11696533,
FT                                ECO:0000269|PubMed:12911626,
FT                                ECO:0000269|PubMed:15040001}.
FT   CONFLICT     62     62       Q -> E (in Ref. 4; CAR58097).
FT                                {ECO:0000305}.
FT   CONFLICT    152    152       K -> R (in Ref. 4; CAR58096).
FT                                {ECO:0000305}.
FT   CONFLICT    196    196       E -> G (in Ref. 4; CAR58095).
FT                                {ECO:0000305}.
FT   CONFLICT    228    228       I -> V (in Ref. 6; BAH12848).
FT                                {ECO:0000305}.
FT   CONFLICT    371    371       P -> R (in Ref. 4; CAR58097).
FT                                {ECO:0000305}.
FT   CONFLICT    381    381       D -> E (in Ref. 1; CAA71138 and 2;
FT                                CAA04146). {ECO:0000305}.
FT   HELIX        95     97       {ECO:0000244|PDB:2R5T}.
FT   STRAND       98    105       {ECO:0000244|PDB:2R5T}.
FT   STRAND      111    117       {ECO:0000244|PDB:2R5T}.
FT   TURN        118    120       {ECO:0000244|PDB:2R5T}.
FT   STRAND      123    130       {ECO:0000244|PDB:2R5T}.
FT   HELIX       131    133       {ECO:0000244|PDB:2R5T}.
FT   STRAND      162    167       {ECO:0000244|PDB:2R5T}.
FT   STRAND      169    177       {ECO:0000244|PDB:2R5T}.
FT   HELIX       184    191       {ECO:0000244|PDB:2R5T}.
FT   HELIX       196    215       {ECO:0000244|PDB:2R5T}.
FT   HELIX       225    227       {ECO:0000244|PDB:2R5T}.
FT   STRAND      228    230       {ECO:0000244|PDB:2R5T}.
FT   STRAND      232    234       {ECO:0000244|PDB:3HDN}.
FT   STRAND      236    238       {ECO:0000244|PDB:2R5T}.
FT   HELIX       245    247       {ECO:0000244|PDB:2R5T}.
FT   STRAND      256    258       {ECO:0000244|PDB:2R5T}.
FT   HELIX       266    269       {ECO:0000244|PDB:2R5T}.
FT   HELIX       277    292       {ECO:0000244|PDB:2R5T}.
FT   HELIX       302    311       {ECO:0000244|PDB:2R5T}.
FT   STRAND      318    320       {ECO:0000244|PDB:2R5T}.
FT   HELIX       322    331       {ECO:0000244|PDB:2R5T}.
FT   HELIX       336    338       {ECO:0000244|PDB:2R5T}.
FT   TURN        340    345       {ECO:0000244|PDB:2R5T}.
FT   HELIX       346    350       {ECO:0000244|PDB:2R5T}.
FT   HELIX       353    355       {ECO:0000244|PDB:2R5T}.
FT   HELIX       360    364       {ECO:0000244|PDB:2R5T}.
SQ   SEQUENCE   431 AA;  48942 MW;  F3697C63AB1F499D CRC64;
     MTVKTEAAKG TLTYSRMRGM VAILIAFMKQ RRMGLNDFIQ KIANNSYACK HPEVQSILKI
     SQPQEPELMN ANPSPPPSPS QQINLGPSSN PHAKPSDFHF LKVIGKGSFG KVLLARHKAE
     EVFYAVKVLQ KKAILKKKEE KHIMSERNVL LKNVKHPFLV GLHFSFQTAD KLYFVLDYIN
     GGELFYHLQR ERCFLEPRAR FYAAEIASAL GYLHSLNIVY RDLKPENILL DSQGHIVLTD
     FGLCKENIEH NSTTSTFCGT PEYLAPEVLH KQPYDRTVDW WCLGAVLYEM LYGLPPFYSR
     NTAEMYDNIL NKPLQLKPNI TNSARHLLEG LLQKDRTKRL GAKDDFMEIK SHVFFSLINW
     DDLINKKITP PFNPNVSGPN DLRHFDPEFT EEPVPNSIGK SPDSVLVTAS VKEAAEAFLG
     FSYAPPTDSF L
//
